program in radiation oncology C Agustin, N Coburn, J Jayamohan, S Chin, S Turner and V Ahern Sydney West Radiation Oncology Network – Crown Princess Mary Cancer Centre Westmead, Blacktown Cancer and Haematology Centre, Nepean Cancer Care Centre, Sydney, New South Wales, Australia, School of Health Sciences, Faculty of Health and Medicine, The University of Newcastle, Newcastle, New South Wales, Australia, Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia

Purpose or Objective: The current standard of care for newly diagnosed papillary thyroid carcinoma invading the trachea is surgical resection followed by radioactive iodine therapy (RAI) and thyroid stimulating hormone suppression. However, the local recurrence rate is high. Several studies reported adjuvant external beam radiotherapy (EBRT) reduced the local recurrence. The benefit of adjuvant EBRT remains controversial. We evaluated the effect of adjuvant EBRT on local control in a single institution database.

S5843rd ESTRO Forum 2015 unlikely to have major clinical impact on cancer cure in the context of metastatic disease.Therefore, combination treatments with immune modifying drugs hold considerable promise for inducing long lasting T cell responses.Attention needs to be given towards optimizing of dose regimens and timing of concurrent treatments.These are necessary steps to unlock a more efficient long term immune response after radiotherapy and make the abscopal effect clinically relevant.

We report the case of a 38-year-old, female patient with neurosarcoidosis involving the pituitary gland and hypothalamus, who was treated with stereotactic radiotherapy (24 Gy in 12 fractions) with an excellent result. The purpose of this case report was to illustrate and discuss the diagnostic and therapeutic challenges faced in the management of neurosarcoidosis, as well as document our experience with the use of stereotactic radiotherapy in the treatment of neurosarcoidosis.

At the Department of Radiation Oncology, Westmead Hospital, between 1980 and 2000, 60 patients with squamous cell carcinoma of anal canal or margin (including 15 with Stage IIIA or IIIB) were treated radically; 55 received chemoradiation (89% were prescribed mitomycin C and 5-fluorouracil). Five-year overall survival was 64% (95% confidence interval (CI): 48-79%), with a median survival of 9.75 years (median follow up 5.6 years, range 5 months to 22.5 years). Ten patients have died of disease. At 2 years the local control rate was 86%, and colostomy-free survival was 83%. Relapse after 2 years was uncommon. Tumour size was the main factor driving outcomes, especially survival. Patients with larger tumours (T > 4 cm) had a hazard ratio for survival of 5.7 (95% CI: 1.8-17). Fourteen (24%) patients experienced treatment interruptions as a result of acute toxicity, including one death from neutropenic sepsis. Seven (12%) patients, in total, experienced one or more late toxicities, grade 3 or above, including four women (all postmenopausal) who developed a radiation-induced bone injury. Most patients with anal cancer can expect to retain a functional sphincter after chemoradiation/radiation. Further studies are in progress to determine the optimal chemoradiation protocol.

This study was aimed at evaluating the consistency of driving advice given by treating clinicians to patients diagnosed with brain tumours. Secondary aims include assessing the awareness of current driving guidelines and whether or not there was a need for more specific guidelines in this group of patients. This was undertaken utilizing a scenario-based postal survey. The results show an overall poor consistency in the answers provided for each case scenario. 73.1% respondents were not aware of any current driving guidelines. Of those who were aware of driving guidelines, 67.7% wanted more specific guidelines to be developed. Possible explanations for this are a lack of awareness of the existence of any driving guidelines and a lack of objective criteria in the current driving guidelines. The authors recommend that the current driving guidelines be comprehensively distributed to clinicians who treat patients with brain tumours, as well as forming a multi-disciplinary working party to develop more specific and objective driving guidelines.